NL-OMON34382
Completed
Not Applicable
A single-center, single-blind study to investigate skin response to sub-therapeutic doses of taspoglutide in GLP-1 analogue naive healthy volunteers - Skin response to subtherapeutic doses of taspoglutide
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Hoffmann-La Roche
- Enrollment
- 6
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Healthy male or female
- •Age : 18\-65 yrs, inclusive
- •BMI : 20\.0\-35\.0 kg/m2, inclusive
Exclusion Criteria
- •Suffering from: hepatitis B, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 90 days from the start of the study. In case of having participated in more than 3 other drug studies (for men) / more than 2 other drug studies (for women) in the 10 months prior to the start of this study, or when having donated more than 1\.5 liters of blood (for men) / more than 1\.0 liters of blood (for women) in the 10 months prior to the start of this study
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
To assess the efficacy of investigational product for its moisturization on healthy human female subjectsCTRI/2013/07/003803Hindustan Unilever Limited40
Not yet recruiting
Not Applicable
A prospective, single-centre study to investigate the role of Optical Coherence Tomography and fractional flow reserve for post coronary angioplasty stent optimisatioHealth Condition 1: I208- Other forms of angina pectorisCTRI/2021/04/032543PGIMER
Not yet recruiting
Not Applicable
A prospective, Single-Centre study to investigate the plaque characteristics of lesions in young Indian patients of =40 yearsHealth Condition 1: I248- Other forms of acute ischemic heart diseaseCTRI/2024/01/061165Dr Nityanand Tripathi
Active, not recruiting
Not Applicable
A single-center, randomized, single-blind study in parallel groups to evaluate the efficacy and safety of a new intravenous iron HES preparation as compared to intravenous iron dextran (Cosmofer) in anemic patientsAnemia in chronic kidney diseaseEUCTR2009-014351-72-ATSerumwerk Bernburg
Active, not recruiting
Phase 1
A single-center, randomized, single-blind study in parallel groups to evaluate the efficacy and safety of a new intravenous iron HES preparation as compared to intravenous iron dextran (Cosmofer®) in EPO (erythropoietin) naïve patients suffering from anemiaEUCTR2009-014351-72-SKSerumwerk Bernburg50